Newsfeed | Navigating EGFR

TGF-α/EGFR-mediated lymphatic metastasis reveals a repositionable therapeutic target in breast cancer

Read more about TGF-α/EGFR-mediated lymphatic metastasis reveals a repositionable therapeutic target in breast cancer

The epidermal growth factor receptor (EGFR) is a well-established oncogenic driver in multiple epithelial cancers, yet its role in breast cancer remains elusive, with EGFR-targeted therapies showing limited clinical efficacy. Here, we demonstrate that EGFR promotes selective lymphatic dissemination in...

ROCK1 inhibition primes anti-tumor immunity in EGFR-mutant NSCLC by triggering PD-L1 degradation mediated by SMURF2

Read more about ROCK1 inhibition primes anti-tumor immunity in EGFR-mutant NSCLC by triggering PD-L1 degradation mediated by SMURF2

Abstract Epidermal growth factor receptor (EGFR) mutations are common in non-small-cell lung cancer (NSCLC) but typically confer poor responses to immunotherapy, likely owing to an inhibitory tumor immune microenvironment. Here, Rho-associated coiled-coil containing protein kinase 1 (ROCK1) was identified as...

Phenotype-specific association of C-reactive protein-to-lymphocyte ratio with incident proteinuric CKD versus isolated eGFR decline: a real-world retrospective cohort study

Read more about Phenotype-specific association of C-reactive protein-to-lymphocyte ratio with incident proteinuric CKD versus isolated eGFR decline: a real-world retrospective cohort study

BackgroundResidual kidney risk persists in hypertensive patients despite guideline-directed blood pressure (BP) management. Whether systemic inflammation is Abstract Background: Residual kidney risk persists in hypertensive patients despite guideline-directed blood pressure (BP) management. Whether systemic inflammation is preferentially associated with the...

Rapid screening of potent and mechanistically insightful repurposable anticancer drugs targeting EGFR for non-small cell lung cancer: machine learning-aided and structure-guided approach

Read more about Rapid screening of potent and mechanistically insightful repurposable anticancer drugs targeting EGFR for non-small cell lung cancer: machine learning-aided and structure-guided approach

Abstract Despite the initial success of EGFR-targeted therapies in non-small cell lung cancer (NSCLC), the emergence of drug resistance remains a significant clinical challenge. While several approved anticancer drugs exist, the development of resistance to current EGFR inhibitors necessitates the...

Deep learning framework for predicting EGFR mutation status from H&E whole slide images in lung adenocarcinoma

Read more about Deep learning framework for predicting EGFR mutation status from H&E whole slide images in lung adenocarcinoma

AbstractBackground Epidermal growth factor receptor (EGFR) mutations are pivotal molecular drivers in lung adenocarcinoma (LUAD) with significant therapeutic implications, yet conventional molecular testing remains costly, time-consuming, and limited by tissue availability. This study aimed to develop and validate a pathology-based...

TBC1D23 drives lymphatic metastasis in pancreatic ductal adenocarcinoma by altering EGFR cell surface dynamics and signaling

Read more about TBC1D23 drives lymphatic metastasis in pancreatic ductal adenocarcinoma by altering EGFR cell surface dynamics and signaling

AbstractBackground Pancreatic ductal adenocarcinoma (PDAC) is among the most devastating malignancies worldwide, characterized by late diagnosis, rapid progression, and dismal survival rates. The discovery of reliable biomarkers for early detection and disease monitoring remains an urgent clinical need. Owing to...

A multi-stage computational pipeline for repurposing FDA-approved drugs: application to EGFR C797S–mutant NSCLC

Read more about A multi-stage computational pipeline for repurposing FDA-approved drugs: application to EGFR C797S–mutant NSCLC

Background/ObjectivesNon-small cell lung cancer (NSCLC) is a leading cause of cancer-related death globally. Resistance to third-generation epidermal growth Abstract Background/Objectives: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death globally. Resistance to third-generation epidermal growth factor receptor...

Identification of a personalized eGFR threshold improves the prediction of kidney failure risk after transplantation

Read more about Identification of a personalized eGFR threshold improves the prediction of kidney failure risk after transplantation

Background Many factors cause kidney transplant graft failure. To identify at-risk patients and tailor treatment, failure risks must be accurately predicted. We are trying to predict the temporal progression of graft function (as treated with estimated glomerular filtration rate) using...

[177Lu]Lu-DOTA-IBA plus EGFR-TKIs versus [177Lu]Lu-DOTA-IBA monotherapy for EGFR-mutated advanced non-small-cell lung cancer (NSCLC) with bone metastases: a prospective study

Read more about [177Lu]Lu-DOTA-IBA plus EGFR-TKIs versus [177Lu]Lu-DOTA-IBA monotherapy for EGFR-mutated advanced non-small-cell lung cancer (NSCLC) with bone metastases: a prospective study

AbstractPurpose To evaluate the efficacy and safety of [177Lu]Lu-DOTA-IBA combined with maintenance EGFR-TKIs versus [177Lu]Lu-DOTA-IBA monotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC) and bone metastases. Methods In this prospective, single-center study, 52 patients with EGFR-mutated NSCLC and...

Subscribe to Newsfeed